在阿尔茨海默氏病中,对mTOR的调节失调
George S Bloom1,2,3, Andrés Norambuena1
1Department of Biology, University of Virginia, Charlottesville, Virginia, USA.
Cytoskeleton (Hoboken, N.J.)
|August 28, 2023
概括
异常的陶酸化,由粉样β寡合体触发,导致神经元重新进入细胞循环并死亡,抑制营养诱导的线粒体激活在阿尔茨海默病 (AD). 这种tau驱动的神经退行会影响关键的细胞过程.
科学领域:
- 神经科学是一个神经科学.
- 细胞生物学 细胞生物学
- 生物化学 生物化学
背景情况:
- 陶蛋白主要存在于神经元中,是阿尔茨海默病 (AD) 中神经纤维纠 (NFT) 的关键组成部分.
- mTOR通路的失调与各种细胞过程和疾病有关.
- 氨基酸β oligomers (AβOs) 是已知的AD病变的贡献者.
研究的目的:
- 为了研究在阿尔茨海默病中mTOR信号失调中的作用.
- 为了阐明超越NFTs的诱导神经退行症的复杂机制.
- 探索对营养诱导的线粒体激活 (NiMA) 的影响.
主要方法:
- 对,mTOR和AD的现有研究进行了审查.
- 分析涉及陶酸化和mTOR的信号网络.
- 实验研究培养的神经元暴露于AβOs.
主要成果:
- 由AβOs诱导的异常 fosforylation,触发后转移神经元重新进入细胞循环,导致最终的细胞死亡.
- 这种tau介导的信号网络抑制了营养诱导的线粒体激活 (NiMA).
- 在神经元中AβO暴露后,tau依赖的细胞循环重新进入和NiMA抑制迅速发生 (数小时内).
结论:
- 陶通过调节mTOR信号,导致神经退行,在AD病变发生过程中发挥关键作用.
- 这些发现表明,诱导的细胞循环再进入和NiMA抑制是AD的早期和基本事件.
- 了解这些驱动机制为阿尔茨海默病提供了潜在的新治疗点.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212


